Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with notable drops including Jian Yong Biotechnology down 81.04% and Antelope Holdings down 25.73% [1] Group 2 - Jian Yong Biotechnology (MENS) closed at 2.920, experiencing a drop of 81.04%, which translates to a decrease of 12.480, with a trading volume of 13.1486 million [1] - Antelope Holdings (AEHL) closed at 1.790, down 25.73%, reflecting a decline of 0.620, with a trading volume of 0.4457 million [1] - 3 E Network Technology (MASK) saw a decrease of 22.96%, closing at 0.2620, down 0.0781, with a trading volume of 0.7766 million [1] - Token Cat (TC) closed at 12.000, down 21.77%, which is a drop of 3.340, with a trading volume of 1.0489 million [1] - Everbright Digital (EDHL) closed at 0.4515, down 17.49%, reflecting a decrease of 0.0957, with a trading volume of 0.2571 million [1]

Summary of Key Points Core Viewpoint - The report highlights a total of 192 financing events disclosed in the week from June 16 to June 22, 2025, involving 143 domestic companies and 49 foreign companies, with a total financing amount of approximately 2327.76 billion RMB. The medical health sector leads in the number of events, while the low-carbon sector leads in financing amount [2]. Domestic Financing Events - The medical health sector disclosed 42 financing events, involving 25 domestic companies and 17 foreign companies, with a total financing amount of approximately 162.68 billion RMB [2]. - Notable domestic events include: - Jian Yong Sheng Ji went public, focusing on plant-based innovative drug development [2]. - Hongze Lake Dashi was acquired by Hongze Lake Construction, providing integrated health services [2]. - Jianfu Tang Chinese Medicine Group was acquired by Jianbei Miao Miao, specializing in traditional Chinese medicine services [2]. - Huashitong Bio was acquired by Kelun Pharmaceutical, focusing on drug development [2]. - Zhejiang Taide Pharmaceutical completed a $10 million Pre-IPO financing round [2]. - Shengda Pharmaceutical received a strategic investment of 260 million RMB, ranking in the top 50 for strategic investments this year [2]. - Other companies like Shuyaqi, Jingzhi Future, and Suzhou Guoke Xin Gan Medical Technology also received strategic investments [2][3]. Foreign Financing Events - The foreign medical health sector saw 1 company go public, 1 company acquired, and 15 companies receiving investments, totaling approximately 137.86 billion RMB [4]. - Key foreign events include: - Caris Life Sciences went public, focusing on biopharmaceutical services [5]. - Verve Therapeutics was acquired, specializing in gene editing technology [6]. - InSilico Medicine raised $123 million in strategic investment, ranking in the top 20 for this year's strategic investments [6]. - Corvia Medical and Sword Health also received significant strategic investments, ranking in the top 50 for their respective rounds [6]. Investment Trends - The report indicates a strong trend in the medical health sector, with numerous companies receiving substantial investments across various stages of financing, reflecting a robust interest in healthcare innovation and technology [2][4][6].

Group 1 - Jyong Biotech Ltd. (MENS) has filed proposed terms to raise $18.8 million from the sale of its common stock in an IPO [1] - The filing is part of an amended F-1/A SEC registration statement [1] Group 2 - IPO Edge, led by an investing group, provides actionable information on growth stocks, including first-look IPO filings and an IPO calendar [2] - The platform also offers a database of U.S. IPOs and a guide to IPO investing, covering the entire IPO lifecycle [2]

As filed with the Securities and Exchange Commission on December 18, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 8 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | - ...

As filed with the Securities and Exchange Commission on November 21, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 7 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | - ...

As filed with the Securities and Exchange Commission on October 31, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 6 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Fang Liu, Esq. VCL Law LLP 1945 Old Gallows Road, Suite 260 Vienna, VA 22182 Tel: 703-919-7285 Approximate date of commencement of proposed sale to the public: as soon as practicable after the effective date of this registration statement. ________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 5 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. As filed with the Securities and Exchange Commission on October 4, 2024 Registration Statement No. 333-277725 If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐ (Exact name o ...

As filed with the Securities and Exchange Commission on September 13, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 4 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | ...

As filed with the Securities and Exchange Commission on August 2, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) Fang Liu, Esq. VCL Law LLP 1945 Old Gallows Road, Suite ...

As filed with the Securities and Exchange Commission on June 21, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | --- | ...